2021
DOI: 10.1016/j.clml.2020.10.002
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
8
2

Year Published

2021
2021
2021
2021

Publication Types

Select...
4

Relationship

2
2

Authors

Journals

citations
Cited by 15 publications
(12 citation statements)
references
References 34 publications
(39 reference statements)
2
8
2
Order By: Relevance
“…After a treatment-free interval of >24 months, disease-free patients appear to have recovered a large portion of the HRQoL lost during treatment and just after its cessation. A similar effect of treatment on HRQoL and post-treatment recovery has previously been reported in patients with acute myeloid leukemia [30] and in real-world studies of French [24] and German patients [26] with multiple myeloma. In adults with ALL, the presence of MRD is widely recognized as the most sensitive prognostic factor for relapse and death regardless of treatment choice and risk classification [14].…”
Section: Discussionsupporting
confidence: 81%
See 1 more Smart Citation
“…After a treatment-free interval of >24 months, disease-free patients appear to have recovered a large portion of the HRQoL lost during treatment and just after its cessation. A similar effect of treatment on HRQoL and post-treatment recovery has previously been reported in patients with acute myeloid leukemia [30] and in real-world studies of French [24] and German patients [26] with multiple myeloma. In adults with ALL, the presence of MRD is widely recognized as the most sensitive prognostic factor for relapse and death regardless of treatment choice and risk classification [14].…”
Section: Discussionsupporting
confidence: 81%
“…Treatment line and response to treatment both had an impact on HRQoL. For example, a close relationship between multiple lines of therapy and HRQoL deterioration has previously been observed in real-world studies of French [24], Spanish [25], and German [26] patients with multiple myeloma. Indeed, the health of patients with relapsed/refractory disease is compromised by the highly toxic multidrug salvage chemotherapy regimens that are commonly used.…”
Section: Discussionmentioning
confidence: 70%
“…Transplantation at 1L also appears to influence subsequent treatment choices: triplet regimens were more frequently prescribed to patients who received an ASCT at 1L than to those who did not. Studies have shown that younger patients, with fewer comorbidities, are likely to tolerate more lines of treatment (including ASCT) and more aggressive regimens [ 1 , 22 , 34 , 35 ]. Access to and reimbursement of treatments also influences treatment patterns [ 1 ].…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, it is important to assess frailty and comorbidities over the disease course in MM tumor boards regularly and if new treatment decisions are being undertaken [6,[44][45][46][47][48]. The assessment of changing performance status over the disease course was described by us in a reference AL-amyloidosis patient [46], in allogeneic stem cell transplantation-receiving MM patients [47], likewise in ASCT-receiving MM patients [48] and with use of quality of life (QoL) tests in various relapse phases [49]. All of these manuscripts verify that functional performance may change over time and is relevant for treatment decisions.…”
Section: Figurementioning
confidence: 99%